Invasive aspergillosis complicated in a patient with non-small cell lung cancer harboring RET fusion during treatment with RET-TKIs: a case report and literature review

Invasive aspergillosis complicated in a patient with non-small cell lung cancer harboring RET fusion during treatment with RET-TKIs: a case report and literature review

Pralsetinib and selpercatinib have been approved as specific tyrosine kinase inhibitors (TKIs) for the treatment of patients with non-small cell lung cancer (NSCLC) harboring rearranged during transfection (RET) fusion and mutation. However, adverse events associated with pralsetinib and selpercatin...

Full description

Bibliographic Details
Main Authors: Kaidiriye Setiwalidi, Yimeng Li, Yuyan Ma, Zhanpeng Hao, Yujia Zhao, Yuxin Zhang, Xuan Liang, Tao Tian, Zhiping Ruan, Yu Yao, Xiao Fu
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-11-01
Series:Frontiers in Oncology
Subjects:
NSCLC
RET
pralsetinib
selpercatinib
invasive aspergillosis
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2024.1431908/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2024.1431908/full

Similar Items